Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Feb '17
|
Lord Arbuthnot of Edrom
|
|
Neuro-bio / NMS:NBIX |
£43.24
|
£127.31
|
194.43%
|
£206,098.51
|
Apr '16
|
Baroness Greenfield
|
|
Neuro-bio / NMS:NBIX |
£46.13
|
£127.31
|
175.98%
|
£193,186.64
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Journey Medical / NCM:DERM |
£3.74
|
£6.35
|
69.79%
|
£118,850.27
|
Jul '23
|
Lord Sassoon
|
|
Haleon / LSE:HLN.L |
£336.10
|
£382.50
|
13.81%
|
£79,663.79
|
Mar '17
|
Lord Lloyd-Webber
|
|
Hikma Pharmaceuticals / LSE:HIK.L |
£2,026.00
|
£2,056.00
|
1.48%
|
£71,036.53
|
Mar '25
|
Lord Fink
|
|
Zoetis / NYQ:ZTS |
£162.82
|
£155.06
|
-4.77%
|
£66,663.80
|
Apr '21
|
Baroness Deech
|
|
Zoetis / NYQ:ZTS |
£168.10
|
£155.06
|
-7.76%
|
£64,569.90
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Evotec / NMS:EVO |
£7.13
|
£3.97
|
-44.32%
|
£38,976.16
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.